Antidepressant Long-Term Studies Prior To Approval Should Not Be Required, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Psychopharmacologic Drugs Advisory Committee finds that the agency’s proposed requirement for long-term data would delay drug marketing.
You may also be interested in...
Long Term Antipsychotic Use In Kids Okay With FDA, But Panel Has Concerns
Not only did three antipsychotic drugs receive FDA advisory committee endorsement June 10 for the acute treatment of schizophrenia and bipolar disorder in pediatric populations, but FDA said that if the sNDAs are approved, it will likely extrapolate pediatric maintenance claims from the adult data
Long Term Antipsychotic Use In Kids Okay With FDA, But Panel Has Concerns
Not only did three antipsychotic drugs receive FDA advisory committee endorsement June 10 for the acute treatment of schizophrenia and bipolar disorder in pediatric populations, but FDA said that if the sNDAs are approved, it will likely extrapolate pediatric maintenance claims from the adult data
FDA Requests Adult Antidepressant Suicidality Data
The agency's review of adult suicidality data will take at least a year to complete, FDA says in a Public Health Advisory. Manufacturers of antidepressants are being asked to review all placebo-controlled trials in adult patients using methodology similar to that used to analyze suicidality in pediatric trials.